AIM: To study collagen-induced arthritis in human leucocyte antigen (HLA)-DR1 transgenic mice lacking endogenous major histocompatibility complex class II molecules (MHC-II) and to determine T cell specificity against the arthritogenic CII(259-273) epitope of type II collagen either unmodified or post-translationally glycosylated at Lys(264). METHODS: Arthritis was induced by immunisation with human type II collagen in complete Freund's adjuvant and measured by footpad swelling, clinical score and histology. T cell responses were assessed by proliferation of spleen and lymph node cells and in antigen presentation assays, using T cell hybridomas specific for the glycosylated and non-glycosylated CII(259-273) epitope. RESULTS: The incidence of arthritis was 50% in DR1-transgenic mice lacking endogenous MHC-II molecules. Recall T cell responses in draining lymph nodes and spleen were consistently greater against the non-glycosylated epitope than to the glycosylated CII(259-273). Most of the T cell hybridomas generated from CII-immunised mice recognised the non-glycosylated CII epitope and this form of the epitope was also presented with 100-fold higher efficiency and 1 h faster kinetics by both macrophages and dendritic cells. CONCLUSION: This study shows that T cell responses to the non-glycosylated epitope of heterologous (human) CII are dominant in HLA-DR1 transgenic mice lacking MHC-II, which could contribute to the pathogenicity of autoimmune arthritis.
AIM: To study collagen-induced arthritis in human leucocyte antigen (HLA)-DR1transgenic mice lacking endogenous major histocompatibility complex class II molecules (MHC-II) and to determine T cell specificity against the arthritogenic CII(259-273) epitope of type II collagen either unmodified or post-translationally glycosylated at Lys(264). METHODS:Arthritis was induced by immunisation with human type II collagen in complete Freund's adjuvant and measured by footpad swelling, clinical score and histology. T cell responses were assessed by proliferation of spleen and lymph node cells and in antigen presentation assays, using T cell hybridomas specific for the glycosylated and non-glycosylated CII(259-273) epitope. RESULTS: The incidence of arthritis was 50% in DR1-transgenic mice lacking endogenous MHC-II molecules. Recall T cell responses in draining lymph nodes and spleen were consistently greater against the non-glycosylated epitope than to the glycosylated CII(259-273). Most of the T cell hybridomas generated from CII-immunised mice recognised the non-glycosylated CII epitope and this form of the epitope was also presented with 100-fold higher efficiency and 1 h faster kinetics by both macrophages and dendritic cells. CONCLUSION: This study shows that T cell responses to the non-glycosylated epitope of heterologous (human) CII are dominant in HLA-DR1transgenic mice lacking MHC-II, which could contribute to the pathogenicity of autoimmune arthritis.
Authors: E C Andersson; B E Hansen; H Jacobsen; L S Madsen; C B Andersen; J Engberg; J B Rothbard; G S McDevitt; V Malmström; R Holmdahl; A Svejgaard; L Fugger Journal: Proc Natl Acad Sci U S A Date: 1998-06-23 Impact factor: 11.205
Authors: V M Corrigall; M D Bodman-Smith; M S Fife; B Canas; L K Myers; P Wooley; C Soh; N A Staines; D J Pappin; S E Berlo; W van Eden; R van Der Zee; J S Lanchbury; G S Panayi Journal: J Immunol Date: 2001-02-01 Impact factor: 5.422
Authors: H Y Kim; W U Kim; M L Cho; S K Lee; J Youn; S I Kim; W H Yoo; J H Park; J K Min; S H Lee; S H Park; C S Cho Journal: Arthritis Rheum Date: 1999-10
Authors: Alexei von Delwig; Daniel M Altmann; John D Isaacs; Clifford V Harding; Rikard Holmdahl; Norman McKie; John H Robinson Journal: Arthritis Rheum Date: 2006-02
Authors: A B Hassell; M J Plant; S Clarke; J Fisher; P W Jones; J Saklatvala; P D Fowler; M F Shadforth; P T Dawes Journal: Br J Rheumatol Date: 1995-01
Authors: E F Rosloniec; D D Brand; L K Myers; K B Whittington; M Gumanovskaya; D M Zaller; A Woods; D M Altmann; J M Stuart; A H Kang Journal: J Exp Med Date: 1997-03-17 Impact factor: 14.307
Authors: Kenneth S Rosenthal; Katalin Mikecz; Harold L Steiner; Tibor T Glant; Alison Finnegan; Roy E Carambula; Daniel H Zimmerman Journal: Expert Rev Vaccines Date: 2015-03-18 Impact factor: 5.217